



#8/P
RECEIVED
6/8/01

JUN 05 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

In re application of :
Klaus STOCKEMANN et al. : Group Art Unit: 1617
Serial No.: 09/392,728 : Examiner: H. Nguyen
Filed: September 9, 1999 :
For: **COMBINATION CONTRACEPTIVE, KITS THAT CONTAIN THE LATTER,
AND A METHOD THAT USES THE LATTER**

REPLY

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated November 30, 2000, please amend the above-referenced application as indicated below and consider the remarks which follow. (a marked-up version of the claims is attached hereto)

IN THE CLAIMS:

Please cancel claim 49 without prejudice or disclaimer.

Please amend claims 5, 10, 11, 24, 25 as indicated below.

AI 5. (Amended) A multi-phase combination preparation of claim 1, wherein the second phase comprises 7 to 14 daily dosage units.

AA 10. (Amended) A multi-phase combination preparation of claim 1, wherein the competitive progesterone antagonist is:

17 α -ethinyl-17 β -hydroxy-11 β -(4-methoxyphenyl)estra-4,9-dien-3-one,

11 β -(4-acetylphenyl)-17 β -hydroxy-17 α -(1-propenyl)estra-4,9-dien-3-one,

(Z)-11 β -(4-acetylphenyl)-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)estra-4,9-dien-3-

one,

11 β -(4-dimethylaminophenyl)-17 β -hydroxy-17 α -(1-propenyl)estra-4,9-dien-3-one,